表紙
市場調査レポート

PharmaPoint:C型肝炎ウイルス(HCV) - 世界の医薬品の予測と市場分析

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

発行 GlobalData 商品コード 296453
出版日 ページ情報 英文 381 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaPoint:C型肝炎ウイルス(HCV) - 世界の医薬品の予測と市場分析 PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日: 2014年05月31日 ページ情報: 英文 381 Pages
概要

当レポートでは、全世界のC型肝炎ウイルス(HCV)治療薬市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態生理
    • 予後
    • 生活の質(QoL)
  • 症状

第4章 疫学

  • リスク要因と共存症
    • 注射薬利用者の場合、C型肝炎の罹患リスクは50倍高くなる
    • 輸血によるC型肝炎の罹患リスクは10.9倍も高くなる
    • 周産期感染を防ぐ方法は現段階では全く存在しない
    • メタボリックシンドローム:C型肝炎患者の一般的な共存症
    • 慢性アルコール中毒は、C型肝炎リスクを大幅に高める
    • B型肝炎とC型肝炎は共通した伝染経路を有し、同時に感染しやすい
    • C型肝炎とHIVの同時感染:治療オプションを複雑化させ、肝臓へのダメージを拡大する
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
    • 日本
    • ブラジル
    • 中国
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 予測の前提条件と手法(C型肝炎の遺伝子型)
    • 利用しなかった情報源
  • 疫学的予測(今後11年間分)
    • C型肝炎の有病数
    • C型肝炎の有病数:年齢別
    • C型肝炎の有病数:性別
    • 年齢調整済みの有病者数
    • C型肝炎の遺伝子型クラス別の分類
  • 議論
    • 疫学的傾向の結論
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 概要
    • 診断・紹介の概要
    • 治療の概要
  • 米国
    • 診断
    • 臨床診療
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル
  • 中国

第6章 競争環境

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • Incivek(テラプレビル)
    • Victrelis(ボセプレビル)
    • Pegasys(ペグインターフェロンα-2a)
    • PegIntron(ペグインターフェロンα-2b)
    • Copegus・Rebetol、および後発薬Ribavirin
    • 治療クラス:インターフェロン

第7章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 薬剤耐性
    • 効能
    • 疾患の認知度
    • 治療費
    • 治療期間の短縮
    • 治療法の単純化
  • アンメットニーズのギャップの分析
  • 市場機会
    • 全遺伝型のHCVウイルス向けの治療法
    • 過小評価されてきた患者人口層への治療
    • 免疫システムの関与

第8章 パイプライン評価

  • 概要
  • 治験マッピング(国別)
  • 相別・治験段階別の治験進行状況
  • パイプラインの戦略的評価
  • 治験中の有望な薬剤
    • SofosbuvirおよびSofosbuvir/Ledipasvir
    • Simeprevir
    • ABT-450+ABT-267およびABT-333
    • FaldaprevirおよびFaldaprevir+BI 207127
    • DaclatasvirおよびDaclatasvir+Asunaprevir
    • Vaniprevir
    • その他の薬剤クラス

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の概要
  • 企業プロファイル
    • Merck
    • Roche
    • Vertex
    • Janssen
    • Gilead
    • AbbVie
    • Bristol-Myers Squibb
    • Boehringer Ingelheim
    • 有望な薬剤を有する追加的企業(全6社)

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 市場促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な出来事
    • 市場促進・阻害要因
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル
  • 中国

第11章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing a direct-acting antiviral (DAA), such as Gilead's Sovaldi (sofosbuvir) or Janssen's Olysio (simeprevir), along with pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and/or ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infections. Sovaldi and Olysio have largely replaced first-generation NS3/4A protease inhibitors, such as Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) due to their increased tolerability, efficacy, and shorter treatment duration. The entrance of next-generation , all-oral HCV therapies is expected to fundamentally alter the HCV treatment algorithm.

Highlights

Key Questions Answered

  • How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm
  • What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade
  • Which novel HCV therapies will face adoption challenges in the market What is the projected uptake of new drugs, such as Merck's MK-5172/MK-8742, over the forecast period
  • Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake
  • How will pricing influence the use of next-generation DAAs
  • Which HCV regimen(s) in development are physicians most excited about

Key Findings

  • Patient awareness is anticipated to increase in response to government education and screening initiatives.
  • Interferon use is predicted to drastically decrease over the next 10 years.
  • The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
  • The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).
  • Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.

Scope

  • Overview of hepatitis C virus (HCV), including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
  • Annualized HCV therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HCV market.
  • Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.
  • Analysis of the current and future market competition in the global HCV therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges.
  • Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HCV therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCV market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HCV therapeutics market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. The risk of contracting HCV is almost 50 times higher among injection drug users
    • 4.1.2. There is a 10.9-fold increased risk of developing HCV infection through a blood transfusion
    • 4.1.3. No current preventative therapy to reduce perinatal HCV transmission
    • 4.1.4. Metabolic syndrome is a common comorbidity in HCV-infected individuals
    • 4.1.5. Chronic alcoholism greatly magnifies the risk of HCC
    • 4.1.6. HBV and HCV share similar modes of transmission, resulting in co-infection
    • 4.1.7. HCV/HIV co-infection complicates treatment options and accelerates liver damage
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Japan
    • 4.2.4. Brazil
    • 4.2.5. China
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Forecast Assumptions and Methods
    • 4.3.3. Forecast Assumptions and Methods (HCV Genotypes)
    • 4.3.4. Sources Not Used
  • 4.4. Epidemiology Forecast for HCV (2012-2022)
    • 4.4.1. Total Prevalent Cases of HCV
    • 4.4.2. Age-Specific Prevalent Cases of HCV
    • 4.4.3. Sex-Specific Prevalent Cases of HCV
    • 4.4.4. Age-Standardized Prevalence of HCV
    • 4.4.5. HCV Genotype Class Distributions
  • 4.5. Discussion
    • 4.5.1. Conclusion on Epidemiology Trends
    • 4.5.2. Limitations of the Analysis
    • 4.5.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Referral Overview
  • 5.2. Treatment Overview
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice
  • 5.10. Brazil
    • 5.10.1. Diagnosis
    • 5.10.2. Clinical Practice
  • 5.11. China
    • 5.11.1. Diagnosis
    • 5.11.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Sovaldi and Sovaldi/Ledipasvir
    • 6.3.2. Olysio
    • 6.3.3. Incivek
    • 6.3.4. Victrelis
    • 6.3.5. Pegasys
    • 6.3.6. PegIntron
    • 6.3.7. Copegus, Rebetol, and Generic Ribavirin
    • 6.3.8. Therapeutic Class: Interferon

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Unmet Needs
    • 7.2.1. Unmet Need: Enhanced Efficacy in Difficult-to-Treat Patient Populations
    • 7.2.2. Unmet Need: Improved Understanding of Drug-Drug Interactions
    • 7.2.3. Unmet Need: Increased Disease Awareness and Diagnosis of HCV
    • 7.2.4. Unmet Need: Reduced Cost of All-Oral Regimens
    • 7.2.5. Unmet Need: Improved Treatment Tolerability
    • 7.2.6. Unmet Need: Simplified Treatment Algorithm
    • 7.2.7. Unmet Need: Shorter Treatment Duration
  • 7.3. Unmet Needs Gap Analysis
  • 7.4. Opportunities
    • 7.4.1. Opportunity: Develop a Pan-Genotypic, All-Oral HCV Regimen
    • 7.4.2. Opportunity: Target Difficult-to-Treat Patient Populations
    • 7.4.3. Opportunity: Eliminate Ribavirin from All-Oral Regimens
    • 7.4.4. Opportunity: Involvement of the Immune System

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Direct-Acting Antivirals (DAAs) in Clinical Development
    • 8.4.1. ABT-450/Ombitasvir + Dasabuvir
    • 8.4.2. Faldaprevir
    • 8.4.3. Daclatasvir, Daclatasvir + Asunaprevir, and Daclatasvir/Asunaprevir/BMS-791325
    • 8.4.4. MK-5172/MK-8742
    • 8.4.5. Vaniprevir
  • 8.5. Other Drug Classes in Clinical Development
    • 8.5.1. Interferon Derivatives
    • 8.5.2. Host-Targeting Therapies

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Merck
    • 9.3.2. Roche
    • 9.3.3. Vertex
    • 9.3.4. Janssen
    • 9.3.5. Gilead
    • 9.3.6. AbbVie
    • 9.3.7. Bristol-Myers Squibb
    • 9.3.8. Boehringer Ingelheim
  • 9.4. Additional Companies with Promising Drugs
    • 9.4.1. Mitsubishi Tanabe Pharmaceutical Corporation
    • 9.4.2. Achillion
    • 9.4.3. Scynexis
    • 9.4.4. Idenix
    • 9.4.5. Presidio
    • 9.4.6. Novartis

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Brazil
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. China
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Percent Drug-Treated Patients
    • 11.4.2. Patient Warehousing
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Selection of Pipeline Agents
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Survey of Prescribing Physicians
  • 11.7. About the Authors
    • 11.7.1. Analysts
    • 11.7.2. Epidemiologist
    • 11.7.3. Therapy Area Director
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Modes of HCV Transmission
  • Table 2: Symptoms of Acute and Chronic HCV Infection
  • Table 3: Risk Factors, Comorbidities, and Complications Associated with HCV Infection
  • Table 4: 9MM, Sources of HCV Prevalence Data Used for the Forecast
  • Table 5: 9MM, Sources of HCV Genotype Data
  • Table 6: Hepatitis C Virus Genotype Description
  • Table 7: 9MM, Prevalent Cases of HCV, Age ≥15 Years, Men and Women, N (Millions), 2012-2022
  • Table 8: 9MM, Prevalent Cases of HCV, By Age, N (Millions), (Row %), 2012
  • Table 9: 9MM, Prevalent Cases of HCV, by Sex, Ages ≥15 Years, N (Row %), 2012
  • Table 10: 9MM, Prevalent Cases of HCV, by Genotype, Ages ≥15 Years, N (Row %), 2012
  • Table 11: HCV Genotypes Present in the 9MM
  • Table 12: General Standard of Care by HCV Genotype
  • Table 13: Treatment Guidelines for HCV by Country
  • Table 14: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2012
  • Table 15: Leading Treatments for HCV, 2014
  • Table 16: Gilead's Sovaldi Ongoing Clinical Trials of Interest
  • Table 17: Product Profile - Sovaldi
  • Table 18: Sovaldi's Most Common Adverse Effects
  • Table 19: Sovaldi SWOT Analysis, 2014
  • Table 20: Global Sales Forecasts ($m) for Sovaldi and Sovaldi/Ledipasvir, 2012-2022
  • Table 21: Janssen's Olysio Clinical Trials of Interest
  • Table 22: Product Profile - Olysio
  • Table 23: Olysio's Efficacy - PILLAR Clinical Trial Results
  • Table 24: Olysio's Safety - Adverse Events Observed in the PILLAR Clinical Trial
  • Table 25: Olysio SWOT Analysis, 2014
  • Table 26: Global Sales Forecasts ($m) for Olysio, 2012-2022
  • Table 27: Product Profile - Incivek
  • Table 28: Efficacy of Incivek in Treatment-Naive Patients (ADVANCE Trial)
  • Table 29: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial)
  • Table 30: Common Incivek Adverse Reactions
  • Table 31: Incivek SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($m) for Incivek, 2012-2022
  • Table 33: Product Profile - Victrelis
  • Table 34: Victrelis Efficacy in Treatment-Naive Patients (SPRINT-2 Trial)
  • Table 35: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial)
  • Table 36: Victrelis SWOT Analysis, 2014
  • Table 37: Global Sales Forecasts ($m) for Victrelis, 2012-2022
  • Table 38: Product Profile - Pegasys
  • Table 39: Antiviral Efficacy of Peginterferon Alfa-2a Compared with Interferon Alfa-2b
  • Table 40: Pegasys SWOT Analysis, 2014
  • Table 41: Global Sales Forecasts ($m) for Pegasys, 2012-2022
  • Table 42: Product Profile - PegIntron
  • Table 43: Antiviral Efficacy of PegIntron Compared With Interferon Alfa-2b
  • Table 44: PegIntron SWOT Analysis, 2014
  • Table 45: Global Sales Forecasts ($m) for PegIntron, 2012-2022
  • Table 46: Effect of Addition of Ribavirin to Peginterferon HCV Therapy
  • Table 47: Ribavirin SWOT Analysis, 2014
  • Table 48: Global Sales Forecasts ($m) for Copegus and Ribavirin, 2012-2022
  • Table 49: Summary of the Minor Therapeutic Classes, 2014
  • Table 50: Overall Unmet Needs - Current Level of Attainment
  • Table 51: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 52: HCV - Clinical Trials by Phase and Status, 2014
  • Table 53: HCV - Late-Stage DAA Pipeline, 2014
  • Table 54: Comparison of Therapeutic Classes in Development for HCV, 2014
  • Table 55: AbbVie's Combination Therapy Clinical Trials of Interest
  • Table 56: Product Profile - AbbVie Combination Therapy
  • Table 57: AbbVie Combination Therapy - AVIATOR Clinical Trial Results
  • Table 58: AbbVie Combination Therapy - Key Phase III Clinical Trial Results
  • Table 59: AbbVie's Combination Therapy SWOT Analysis, 2014
  • Table 60: Global Sales Forecasts* ($m) for AbbVie Combination Therapy, 2012-2022
  • Table 61: BI's Faldaprevir Clinical Trials of Interest
  • Table 62: Product Profile - Faldaprevir
  • Table 63: Faldaprevir SWOT Analysis, 2014
  • Table 64: Global Sales Forecasts ($m) for Faldaprevir, 2012-2022
  • Table 65: BMS' Combination Therapy Clinical Trials of Interest
  • Table 66: Product Profile - BMS' Combination Therapy
  • Table 67: Efficacy of Daclatasvir in Treatment-Naive Patients (COMMAND-1 Trial)
  • Table 68: Daclatasvir and Asunaprevir Quad Therapy Efficacy
  • Table 69: Daclatasvir Triple Therapy Adverse Events
  • Table 70: BMS Combination Therapy SWOT Analysis, 2014
  • Table 71: Global Sales Forecasts ($m) for BMS' Combination Therapy and Peginterferon Lambda, 2012-2022
  • Table 72: Merck's Combination Therapy Clinical Trials of Interest
  • Table 73: Product Profile - MK-5172/MK-8742
  • Table 74: MK-5172/MK-8742 SWOT Analysis, 2014
  • Table 75: Global Sales Forecasts ($m) for MK-5172/MK-8742, 2012-2022
  • Table 76: Merck's Vaniprevir Clinical Trials of Interest
  • Table 77: Product Profile - Vaniprevir
  • Table 78: Vaniprevir SWOT Analysis, 2014
  • Table 79: Global Sales Forecasts ($m) for Vaniprevir, 2012-2022
  • Table 80: Comparison of Peginterferon Lambda with Peginterferon Alfa (EMERGE Trial)
  • Table 81: Efficacy of Alisporivir in Treatment-Naive HCV GT2/3 Patients (VITAL-1 Trial)
  • Table 82: Key Companies in the HCV Market, 2014
  • Table 83: Merck's HCV Portfolio Assessment, 2014
  • Table 84: Merck SWOT Analysis, 2014
  • Table 85: Roche's HCV Portfolio Assessment, 2014
  • Table 86: Roche SWOT Analysis, 2014
  • Table 87: Vertex's HCV Portfolio Assessment, 2014
  • Table 88: Vertex SWOT Analysis, 2014
  • Table 89: Janssen's HCV Portfolio Assessment, 2014
  • Table 90: Janssen SWOT Analysis, 2014
  • Table 91: Gilead's HCV Portfolio Assessment, 2014
  • Table 92: Gilead SWOT Analysis, 2014
  • Table 93: AbbVie's HCV Portfolio Assessment, 2014
  • Table 94: AbbVie SWOT Analysis, 2014
  • Table 95: BMS' HCV Portfolio Assessment, 2014
  • Table 96: BMS' SWOT Analysis, 2014
  • Table 97: BI's HCV Portfolio Assessment, 2014
  • Table 98: BI SWOT Analysis, 2014
  • Table 99: Mitsubishi Tanabe Pharma's HCV Portfolio Assessment, 2014
  • Table 100: Achillion's HCV Portfolio Assessment, 2014
  • Table 101: Scynexis' HCV Portfolio Assessment, 2014
  • Table 102: Idenix's HCV Portfolio Assessment, 2014
  • Table 103: Presidio's HCV Portfolio Assessment, 2014
  • Table 104: Novartis' HCV Portfolio Assessment, 2014
  • Table 105: Global Sales Forecasts ($m) for HCV, 2012-2022
  • Table 106: HCV Market - Drivers and Barriers, 2012-2022
  • Table 107: Sales Forecasts ($m) for HCV in the US, 2012-2022
  • Table 108: Key Events Impacting Sales for HCV in the US, 2012-2022
  • Table 109: US HCV Market - Drivers and Barriers, 2012-2022
  • Table 110: Sales Forecasts ($m) for HCV in France, 2012-2022
  • Table 111: Key Events Impacting Sales for HCV in France, 2012-2022
  • Table 112: French HCV Market - Drivers and Barriers, 2012-2022
  • Table 113: Sales Forecasts ($m) for HCV in Germany, 2012-2022
  • Table 114: Key Events Impacting Sales for HCV in Germany, 2012-2022
  • Table 115: German HCV Market - Drivers and Barriers, 2012-2022
  • Table 116: Sales Forecasts ($m) for HCV in Italy, 2012-2022
  • Table 117: Key Events Impacting Sales for HCV in Italy, 2012-2022
  • Table 118: Italian HCV Market - Drivers and Barriers, 2012-2022
  • Table 119: Sales Forecasts ($m) for HCV in Spain, 2012-2022
  • Table 120: Key Events Impacting Sales for HCV in Spain, 2012-2022
  • Table 121: Spanish HCV Market - Drivers and Barriers, 2012-2022
  • Table 122: Sales Forecasts ($m) for HCV in the UK, 2012-2022
  • Table 123: Key Events Impacting Sales for HCV in the UK, 2012-2022
  • Table 124: UK HCV Market - Drivers and Barriers, 2012-2022
  • Table 125: Sales Forecasts ($m) for HCV in Japan, 2012-2022
  • Table 126: Key Events Impacting Sales for HCV in Japan, 2012-2022
  • Table 127: Japanese HCV Market - Drivers and Barriers, 2012-2022
  • Table 128: Sales Forecasts ($m) for HCV in Brazil, 2012-2022
  • Table 129: Key Events Impacting Sales for HCV in Brazil, 2012-2022
  • Table 130: Brazilian HCV Market - Drivers and Barriers, 2012-2022
  • Table 131: Sales Forecasts ($m) for HCV in China, 2012-2022
  • Table 132: Key Events Impacting Sales for HCV in China, 2012-2022
  • Table 133: Chinese HCV Market - Drivers and Barriers, 2012-2022
  • Table 134: Key Launch Dates
  • Table 135: Key Patent Expiries
  • Table 136: Physicians Surveyed, By Country

List of Figures

  • Figure 1: HCV Genome and Polyprotein Composition
  • Figure 2: HCV Lifecycle Overview
  • Figure 3: 9MM, Prevalent Cases of HCV, Ages ≥15 Years, Men and Women, N (Millions), 2012-2022
  • Figure 4: 9MM, Prevalent Cases of HCV, by Age, N (Millions), 2012
  • Figure 5: 9MM, Prevalent Cases of HCV, by Sex, N (Millions), 2012
  • Figure 6: 9MM, Age-Standardized Prevalence of HCV, Ages ≥15 Years, by Sex, %, 2012
  • Figure 7: HCV Therapeutics - Clinical Trials by Country, 2014
  • Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022
  • Figure 9: Company Portfolio Gap Analysis in HCV, 2012-2022
  • Figure 10: Global Sales for HCV Therapeutics by Country, 2012-2022
  • Figure 11: Sales for HCV Therapeutics in the US by Drug Class, 2012-2022
  • Figure 12: Sales for HCV Therapeutics in France by Drug Class, 2012-2022
  • Figure 13: Sales for HCV Therapeutics in Germany by Drug Class, 2012-2022
  • Figure 14: Sales for HCV Therapeutics in Italy by Drug Class, 2012-2022
  • Figure 15: Sales for HCV Therapeutics in Spain by Drug Class, 2012-2022
  • Figure 16: Sales for HCV Therapeutics in the UK by Drug Class, 2012-2022
  • Figure 17: Sales for HCV Therapeutics in Japan by Drug Class, 2012-2022
  • Figure 18: Sales for HCV Therapeutics in Brazil by Drug Class, 2012-2022
  • Figure 19: Sales for HCV Therapeutics in China by Drug Class, 2012-2022
Back to Top